AI Article Synopsis
- The report details a case of an 87-year-old woman with metastatic extraskeletal myxoid chondrosarcoma (EMC) who underwent treatment after her initial surgical amputation for a large tumor in her ankle.
- High-dose-rate interstitial brachytherapy (HDR-ISBT) was administered to manage metastases in her inguinal lymph node, breast, and popliteal fossa, providing significant control over the tumors.
- The HDR-ISBT treatment (30 Gy/2 fractions in 1 day) proved effective for palliative care and long-term control of the disease without severe side effects.
Article Abstract
We report on a patient with metastatic extraskeletal myxoid chondrosarcoma (EMC), who was treated with palliative high-dose-rate (HDR) interstitial brachytherapy (ISBT). The patient was an 87-year-old woman who underwent an amputation for a bulky tumor in her right ankle joint. EMC was histopathologically confirmed. She presented with a large right inguinal lymph node metastasis of EMC 16 months after surgery. Palliative HDR-ISBT (30 Gy/2 fractions in 1 day) for the right inguinal lymph node metastasis was administered to shorten treatment period. Additional HDR-ISBT (30 Gy/2 fractions in 1 day) was administered for the management of subsequent subcutaneous metastasis to the right breast and right popliteal fossa. HDR-ISBT provided significant long-term control of the recurrent tumor in all three sites, without severe acute and late toxicity. Thus, HDR-ISBT regimen of 30 Gy/2 fractions in 1 day can be a suitable option for both palliation and long-term local control for patients with metastatic EMC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044308 | PMC |
| http://dx.doi.org/10.5114/jcb.2022.115161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!